Lingnan Modern Clinics in Surgery ›› 2018, Vol. 18 ›› Issue (02): 123-127.DOI: 10.3969/j.issn.1009-976X.2018.02.001
Next Articles
CHAI Jie, YAO Herui
Contact:
柴洁，姚和瑞*
通讯作者:
基金资助:
国家自然科学基金;国家自然科学基金;国家自然科学基金;广东省自然科学基金;广州市科技计划;广州市科技计划
Abstract: Breast cancer is one of the most common malignant disease in China. HER2 positive meta?static breast cancer accounted for 25% to 30%. The prognosis of HER2 positive metastatic breast cancer is poor, how to improve the therapeutic effect of HER2 positive metastatic breast cancer have vital clinical-significance, including optimize targeted therapy, selection of chemotherapy and strategy beyond first-line therapy. This article based on the 2017 breast cancer conference and reviewed the latest progress of HER2 positive metastatic breast cancer.
Key words: annual progress, HER2 positive, metastatic breast cancer, targeted optimization
摘要： 乳腺癌是我国女性发病率最高的恶性肿瘤，其中HER2阳性转移性乳腺癌在晚期乳腺癌占比为25%~30%。HER2阳性乳腺癌患者预后差，如何提高HER2阳性转移性乳腺癌的治疗效果，包括优化靶向治疗、化疗药物的选择、后线治疗的策略等具有重要的临床意义。本文基于2017年各大乳腺癌会议，针对HER2阳性转移性乳腺癌在临床中的常见问题，阐述HER2阳性转移性乳腺癌治疗策略的新进展。
关键词: HER2阳性, 转移性乳腺癌, 靶向优化, 年度进展
CLC Number:
R737.9
CHAI Jie, YAO Herui. Annual progress of HER2 positive metastatic breast cancer[J]. Lingnan Modern Clinics in Surgery, 2018, 18(02): 123-127.
柴洁，姚和瑞*. HER2阳性转移性乳腺癌治疗年度进展[J]. 岭南现代临床外科, 2018, 18(02): 123-127.
0 / / Recommend
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.lingnanwaike.com/EN/10.3969/j.issn.1009-976X.2018.02.001
http://www.lingnanwaike.com/EN/Y2018/V18/I02/123
